MedPath

Pediatric Acute Kidney Injury in COVID-19

Completed
Conditions
Acute Kidney Injury
COVID
Registration Number
NCT04466306
Lead Sponsor
Children's Healthcare of Atlanta
Brief Summary

This study is an observational registry of children with or suspected to have SARS CoV2 (COVID-19) admitted to pediatric intensive care units (PICU). This registry will help describe the prevalence, rate and severity of acute kidney injury (AKI) in children with Severe Acute Respiratory Syndrome Coronavirus-2(SARS CoV2) across the world. The registry will be developed using a point prevalence methodology and then full retrospective review. Once a week, from April through June 2020, data collection will occur in "real-time" to estimate a weekly point prevalence of AKI and renal replacement therapy (RRT). The operational definition of "patients under investigation" (PUIs) will be used to identify the denominator of patients to be studied. The PUIs will be cohorted into SARS CoV2 test positive, test negative, test pending, or test unavailable. The primary aim of this study is to deliver a global, objective data driven analysis of the burden of AKI in virus positive patients or patients under investigation (PUI) who are admitted to the pediatric intensive care unit.

Detailed Description

The primary purpose of the data collection will be to provide a descriptive analysis of the burden and characteristics of AKI in children with SARS-CoV2 proven or suspected infection across the world. This is a prospective, point prevalence study. Data collection will occur once a week during the months of April through June 2020.

The protocol for the point prevalence is for each individual participating site to conduct a surveillance study on predetermined dates of their intensive care units (pediatric medical, surgical, cardiac ICUs) for patients by the inclusion and exclusion criteria. The study is strictly observational. Data will only be captured on the predetermined dates listed. The dates have been chosen to reflect the estimated surge and peak of the virus spread in North America, Europe, Africa, Asia, and Australia. The rationale for performing an urgent point prevalence estimation study first, includes the following: a) there is almost no knowledge on AKI rate, severity of AKI or how current pandemic-setting AKI phenotype differs from what we know of AKI in children prior to the pandemic. A rapidly-performed, high feasibility-designed point prevalence estimation study, with minimal data collection will provide rapid, almost instantaneous dissemination of results to the international community. Based on the results of this study, a follow-up study is planned for a full retrospective data collection of all viral positive patients. Understanding the burden of pediatric AKI during this pandemic within the current context of acute health burden in the healthcare settings and enable planning and feasibility evaluation for quality of care measures and potentially for upcoming technology needs and/or sharing of RRT technology with adult care units; b) an urgent point-prevalence estimation study with minimal but key data collection will inform on any changes to design, sample size requirements or data points for the larger granular longitudinal retrospective study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Patient less than or equal to 25 years of age
  • Receiving clinical care in the pediatric intensive care unit (PICU) on a study day in April - June 2020
  • Patient considered a "Person Under Investigation" and/or tested positive for SARS-CoV2 (COVID-19)
Read More
Exclusion Criteria

• None

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Acute Kidney Injury (AKI)14 days

Kidney Disease Improving Global Outcomes (KDIGO) Staged AKI by serum creatinine or urine output

Secondary Outcome Measures
NameTimeMethod
Fluid overloadDay of Enrollment

\>20% fluid overload as defined as the net fluid balance since ICU admission (in liters) divided by ICU admission weight

Survival14 days

Survival to ICU discharge or Day 14

Rate of nephrotoxic medication exposureDay of Enrollment

The exposure of enrolled patients to known nephrotoxic medications, including diuretics

Rate of Extracorporeal Therapy Requirement14 days

The use of extracorporeal membrane oxygenation (ECMO) and/or renal replacement therapy

Trial Locations

Locations (47)

Yale New Haven Children's Hospital

🇺🇸

New Haven, Connecticut, United States

Stony Brook Children's Hospital

🇺🇸

Stony Brook, New York, United States

University Children's Hospital

🇷🇸

Belgrade, Serbia

Stollery Children's Hospital

🇨🇦

Edmonton, Alberta, Canada

Levine Children's Hospital

🇺🇸

Charlotte, North Carolina, United States

UF Health Shands Children's Hospital

🇺🇸

Gainesville, Florida, United States

King's College Hospital NHS

🇬🇧

London, United Kingdom

Golisano Children's Hospital - University of Rochester Medicine

🇺🇸

Rochester, New York, United States

McMaster Children's Hospital

🇨🇦

Hamilton, Ontario, Canada

Penn State Children's Hospital

🇺🇸

Hershey, Pennsylvania, United States

St. Louis Children's Hospital of Washington University

🇺🇸

Saint Louis, Missouri, United States

Institute for Mother and Child Healthcare

🇷🇸

Belgrade, Serbia

Birmingham Children's Hospital NHS

🇬🇧

Birmingham, United Kingdom

Oishei Children's Hospital of Buffalo

🇺🇸

Buffalo, New York, United States

Great Ormond Street Hospital NHS

🇬🇧

London, United Kingdom

Dana-Dwek Children's Hospital

🇮🇱

Tel Aviv, Israel

Alder Hey Children's Hospital NHS

🇬🇧

Liverpool, United Kingdom

Beaumont Children's Hospital

🇺🇸

Royal Oak, Michigan, United States

St. George's University Hospital NHS

🇬🇧

London, United Kingdom

Soroka University Medical Center

🇮🇱

Be'er Sheva, Israel

Shizuoka Children's Hospital

🇯🇵

Shizuoka, Japan

Hospital 12 de Octubre

🇪🇸

Madrid, Spain

UCLA Mattel Children's Hospital

🇺🇸

Los Angeles, California, United States

The Hospital for Sick Children (SickKids)

🇨🇦

Toronto, Ontario, Canada

Children's Healthcare of Atlanta

🇺🇸

Atlanta, Georgia, United States

Comer Children's Hospital - UChicago Medicine

🇺🇸

Chicago, Illinois, United States

Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

UPMC Children's Hospital of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

Seattle Children's Hospital

🇺🇸

Seattle, Washington, United States

Children's Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Rady Children's Hospital San Diego

🇺🇸

San Diego, California, United States

Duke Children's Hospital and Health Center

🇺🇸

Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Children's Mercy

🇺🇸

Kansas City, Kansas, United States

Children's Hospital of Alabama

🇺🇸

Birmingham, Alabama, United States

Arkansas Children's Research Institute

🇺🇸

Little Rock, Arkansas, United States

Cedars-Sinai Maxine Dunitz Children's Health Center

🇺🇸

Los Angeles, California, United States

Lucile Packard Children's Hospital Standford

🇺🇸

Palo Alto, California, United States

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

University of Iowa Stead Family Children's Hospital

🇺🇸

Iowa City, Iowa, United States

C.S. Mott Children's Hospital

🇺🇸

Ann Arbor, Michigan, United States

Medical University of South Carolina Shawn Jenkins Children's Hospital

🇺🇸

Charleston, South Carolina, United States

Helen DeVos Children's Hospital

🇺🇸

Grand Rapids, Michigan, United States

Lifespan Hasbro Children's Hospital

🇺🇸

Providence, Rhode Island, United States

John Hopkins Children's Center

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath